Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.

PloS one - 1 Jan 2023

Pang Jia Meng, Chien Po-Chen, Kao Ming-Chien, Chiu Pei-Yun, Chen Pin-Xu, Hsu Yu-Ling, Liu Chengyang, Liang Xiaowei, Lin Kai-Ti

Abstract excerpt

RAS, the most frequently mutated oncogene that drives tumorigenesis by promoting cell proliferation, survival, and motility, has been perceived as undruggable for the past three decades. However, intense research in the past has mainly focused on KRAS mutations, and targeted therapy for NRAS mutations remains an unmet medical need. NRAS mutation is frequently observed in several cancer types, including melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia

Share to Melanoma

Share to Membrane Proteins

Share to MicroRNAs

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 37083947
DOI: 10.1371/journal.pone.0284744
PMCID: PMC10120925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.PMID 37083947Read ↗

Nras in melanoma: targeting the undruggable target.Semantic proximity Read ↗

Inhibition and degradation of NRAS with a pan-NRAS monobody.Semantic proximity Read ↗

NRAS mutant melanoma--undrugable?Semantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.Semantic proximity Read ↗

Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.Semantic proximity Read ↗

Targeting NRAS in melanoma.Semantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.Semantic proximity Read ↗

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.Semantic proximity Read ↗

Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.Semantic proximity Read ↗

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.